SynopsisH2 blockers are a group of medicines that reduce the amount of acid produced by the cells in the lining of the stomach. They are also called 'histamine H2-receptor antagonists' but are commonly called H2 blockers. The global Histamine H2-receptor Antagon.....
SynopsisH2 blockers are a group of medicines that reduce the amount of acid produced by the cells in the lining of the stomach. They are also called 'histamine H2-receptor antagonists' but are commonly called H2 blockers. The global H2 Antagonists or H2 blockers.....
SynopsisEpileptic Seizure Monitor System is a seizure-detection system that can be used long-term and in home situations for early intervention and prevention of seizure related side effects including SUDEP The global Epileptic Seizure Monitoring System market w.....
SynopsisIcotinib (trade name Conmana) is a highly selective, first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). Icotinib is approved for use as first-line monotherapy in patients with non-small-cell lung cancer with somatic EGFR mu.....
SynopsisIcotinib (trade name Conmana) is a highly selective, first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). Icotinib is approved for use as first-line monotherapy in patients with non-small-cell lung cancer with somatic EGFR mu.....
SynopsisAlectinib is an oral drug that blocks the activity of anaplastic lymphoma kinase (ALK) and is used to treat non-small-cell lung cancer (NSCLC). The global Alectinib Drugs market was valued at US$ 1452 million in 2023 and is anticipated to reach US$ 3171......
SynopsisRegofinil is a new type of multi-kinase small molecule inhibitor, currently it has been approved for the treatment of metastatic colorectal cancer The global Regofinil market was valued at US$ 656.9 million in 2023 and is anticipated to reach US$ 1384.8 .....
SynopsisOsimertinib, sold under the brand name Tagrisso, is a medication used to treat non-small-cell lung carcinomas with specific mutations. It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor. The global Osimertinib Drugs marke.....
SynopsisAnlotinib is a new, orally administered tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptors (PDGFR), and c-kit. The global Anlotini.....
SynopsisFoods for special medical purposes (FSMP) are a sub-category of foods intended for particular nutritional uses (PARNUT), also called “dietetic foods.” FSMPs are intended for the dietary management of diseases in patients with impaired digestive function such a.....
